



PRESS RELEASE

Corteria Pharmaceuticals appoints Mark Pruzanski as Chairman of its Board of Directors

Paris (France), 05 January 2024 - Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for heart failure and obesity, today announced it has appointed Mark Pruzanski, MD, as Chairman of its Board of Directors. He replaces Thierry Laugel, Managing Partner at Kurma Partners, who remains a member of the Board.

Dr. Pruzanski has more than 30 years of experience as a life sciences executive, entrepreneur and investor. He most recently served as Chairman and CEO of Versanis Bio, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of obesity and other cardiometabolic diseases, which was acquired by Eli Lilly in July 2023. He founded Intercept Pharmaceuticals and was the company’s CEO until 2021, having led its evolution from drug discovery stage to a global development and commercial organization with a focus on addressing chronic liver diseases. He serves as a Board member of several private and public biotechnology companies, the Emerging Companies Section of the Biotechnology Innovation Organization (BIO), and the Foundation for Defense of Democracies, a non-profit policy institute focusing on foreign policy and national security.

Dr. Pruzanski received his M.D. from McMaster University in Hamilton, Canada, a M.A. degree in International Affairs from the Johns Hopkins University School of Advanced International Studies in Bologna, Italy and Washington, D.C., and a bachelor’s degree in Political Science from McGill University in Montreal, Canada.

“We are thrilled to welcome Mark as the Chairman of the Board of Directors,” said Philip Janiak, founder and CEO of Corteria Pharmaceuticals. *“Mark brings extensive expertise in drug development with a solid track record in the biotechnology industry. His strategic vision, outstanding leadership and passion for innovation make him a valuable addition to Corteria as we continue our mission to advance innovative therapeutic solutions for heart failure and obesity.”*

“It’s a privilege to join the Board of Corteria,” said Mark Pruzanski. “This is an exciting time in the company’s evolution as it brings its exciting first-in-class assets into the clinic and on the heels of its recent Series A financing led by top tier biotech investors. I am looking forward to working with Philip and the rest of the Board to help ensure Corteria’s future success.”

About Corteria Pharmaceuticals

Founded in 2021, Corteria is a privately held biopharmaceutical company developing first-in-class drugs with an initial focus on the treatment of heart failure. Despite improvements in the management of this serious disease, the prevalence of heart failure keeps increasing with more than 60 million patients worldwide and there are large subpopulations of patients who are poorly served by currently available treatments.

More information available at: www.corteriapharma.com

Investors/media contacts

Stéphane Durant des Aulnois, CFO

Corteria Pharmaceuticals

stephane.durant_des_aulnois@corteriapharma.com

Andrew Lloyd & Associates

Juliette Schmitt / Celine Gonzalez

juliette@ala.associates / celine@ala.associates

UK: +44 1273 952 481

US: +1 203 724 595